Distigmine Bromide
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13694 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 26 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | myasthenia gravis with thymus hyperplasia | KG + DL |
| 2 | myasthenia, limb-girdle, autoimmune | KG + DL |
| 3 | neonatal myasthenia gravis | KG + DL |
| 4 | autoimmune disease of peripheral nervous system | KG + DL |
| 5 | disease of receptor activity | KG + DL |
| 6 | hypersplenism (disease) | KG + DL |
| 7 | atypical hemolytic-uremic syndrome with B factor anomaly | KG + DL |
| 8 | fetal akinesia deformation sequence | KG + DL |
| 9 | congenital myasthenic syndrome with tubular aggregates | KG + DL |
| 10 | myasthenia, congenital, refractory to acetylcholinesterase inhibitors | KG + DL |
| 11 | myasthenic syndrome, congenital, 24, presynaptic | KG + DL |
| 12 | myasthenic syndrome, congenital, 25, presynaptic | KG + DL |
| 13 | acute liver failure | KG + DL |
| 14 | enterocolitis (disease) | KG + DL |
| 15 | congenital myasthenic syndromes with glycosylation defect | KG + DL |
| 16 | Takayasu arteritis | KG + DL |
| 17 | polyarteritis nodosa | KG + DL |
| 18 | splenic infarction | KG + DL |
| 19 | bronchitis | KG + DL |
| 20 | granulomatosis with polyangiitis | KG + DL |
| 21 | gastroenteritis | KG + DL |
| 22 | large intestine disease | KG + DL |
| 23 | small intestine disease | KG + DL |
| 24 | irritable bowel syndrome | KG + DL |
| 25 | immune-mediated acquired neuromuscular junction disease | KG + DL |
| 26 | myasthenic syndrome, congenital, 1B, fast-channel | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.